Introduction
The absorption of many therapeutics can be affected by the expression and activity of drug transporters in the intestine. The first drug transporter described was P-glycoprotein (Pgp, also referred to as MDR1or ABCB1) (Juliano and Ling, 1976; Ueda et al., 1986) and is encoded by the Abcb1a and Abcb1b genes in mice (Schinkel et al., 1994) . P-gp is an ATPdependent efflux pump that actively transports xenobiotics from cells (Gottesman and Pastan, 1993) . P-gp transports a wide range of structurally different therapeutics including colchicine, tacrolimus, quinidine, chemotherapeutic drugs (such as etoposide, doxorubicin, and vinblastine), cardiac glycosides (such as digoxin), glucocorticoids (such as dexamethasone), and HIV-type 1 antiretroviral therapy drugs (Aller et al., 2009) . Overexpression of Abcb1a and -1b can confer drug resistance by increasing efflux of these drugs from cells (Dhir et al., 1990; Raymond et al., 1990) and is a well-established cause of resistance to cancer chemotherapeutic drugs. Abcb1a is mainly expressed in gastrointestinal tract, testis, and capillaries within the brain (Cui et al., 2009) . In humans, the ABCB1 gene encodes P-gp, which has a similar tissue distribution pattern, as mice (Cordon-Cardo et al., 1989; Thiebaut et al., 1987; Thiebaut et al., 1989) . Thus, it is thought that P-gp functions to protect the body, limiting xenobiotic intestinal absorption and limiting the distribution to the central nervous system and germ cells. In enterocytes, P-gp is located on the apical surface where it transports xenobiotics back into the intestinal lumen, resulting in limited xenobiotic absorption (Croop et al., 1989; Takano et al., 2006) . Because P-gp is known to transport a variety of therapeutics, altering its intestinal expression or activity may alter the bioavailability of a large range of therapeutics.
There is wide variation in the response of humans to therapeutics, both beneficially and adversely. A factor that is often proposed to contribute to this variation is diet (Boullata D , 2012; Otles and Senturk, 2014; Won et al., 2010) . Until recently, knowledge regarding food-drug interactions was primarily based on anecdotal accounts. But recent studies have now proven examples of foods that can alter the pharmacokinetics of drugs. For example grapefruit juice inhibits Cytochrome P450 3A4 (CYP3A4), which results in increased bioavailability of drugs such as saquinavir, cyclosporine, and felodipine (Seden et al, 2010) .
Phytochemicals in grapefruit juice, such as bergamottin and quercetin, and green tea catechins inhibit the cellular efflux of P-gp substrates in vitro (Zhou et al., 2004) . Furthermore, the amount of protein in the diet can influence drug metabolism and glomerular filtration. For example, in human volunteers, a protein-restricted diet resulted in a 70% decrease in the clearance of oxipurinol and uric acid (Berlinger et al., 1985) .
There is a lack of knowledge regarding the effect of decreased calorie consumption on the pharmacokinetics of drugs. However we previously reported that mice on a calorie restricted diet, had a profound effects on gene expression in liver (Renaud et al., 2014) . More specifically, we found that calorie restriction substantially increased hepatic Abcb1a transcripts. These results raised the question of whether calorie restriction alters the expression of Abcb1a in the intestine, where this transporter is known to have a major impact on xenobiotic absorption. In this report, we reveal that calorie restriction causes decreased absorption of digoxin -likely through a mechanism of calorie restriction-induced expression of P-gp. These results support the hypothesis that diet is an important regulator of drug absorption.
8 on these diets for 3 weeks, after which they were either used for RNA studies or digoxin absorption studies.
Tissue Collection for RNA Studies
In the morning (8:00-10:00 A.M.) mice were euthanized with pentobarbital and their small intestines were collected. Fecal matter was flushed from the small intestines using a saline solution. Small intestines were divided into 3 equal parts -duodenum, jejunum, and ileum then immediately frozen in liquid nitrogen and stored at -80°C until further analysis.
RNA Extraction
RNA was isolated from frozen intestine using RNA Isolation Reagent RNA-Bee following the manufacturer's protocol. Using a NanoDrop1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE), RNA concentrations were quantified at a wavelength of 260nm.
Messenger RNA Quantification (RT-qPCR)
To perform real-time PCR, we first reverse transcribed RNA to cDNA using an Applied Biosystems High Capacity Reverse Transcriptase kit. In brief, equal volumes of 2X reverse transcriptase, 50 ng/µl RNA, and random primers were mixed and placed in a Mastercycler 
Digoxin absorption experiments
The protocol followed for these experiments was adapted from an earlier study (Mayer et al., 1996) . Each mouse was given 0.2 mg/kg digoxin labeled with [ 3 H]-digoxin (1 µCi/30g body weight) by oral gavage. Wild-type mice were euthanized 1, 2, 4, or 12 hrs after digoxin administration, and Abcb1a/b-null mice were euthanized 4 hrs after digoxin administration.
Blood was collected by orbital bleeding into heparinized tubes and centrifuged for 10 min at 2000 xg to isolate plasma. Plasma (100 µl) was transferred to 4 ml of Ultima Gold high counting efficiency scintillation cocktail. The entire intestine from stomach to rectum (including fecal matter) was also collected, weighed, and homogenized in 4% (w/v) BSA. Thus, all intestine samples include the fecal matter. From here on in we will refer to the intestine + contents samples as "intestine". Two-hundred µl of intestine homogenate was added to 4 ml Ultima Gold high counting efficiency scintillation cocktail. Radioactivity was quantified by liquid In mice fed ad libitum, compared to wild-type mice, Abcb1a/b-null mice had lower digoxin concentrations in their intestines (974 vs 265 ng digoxin/gram intestine) and higher digoxin concentrations in plasma (0.035 vs 0.100 mean ng digoxin/μl plasma) 4 hrs after digoxin administration (Figure 2 and 3 ). This result was as predicted because Abcb1a-null mice do not have the capacity to efflux digoxin via P-gp, thus resulting in increased digoxin absorption.
No statistical differences in the concentrations of digoxin in intestine or plasma were observed between ad libitum fed and calorie restricted Abcb1a/b-null mice (Fig. 3) . Thus, these results support the findings that decreased digoxin absorption in calorie restricted wildtype mice is likely due to increased intestinal P-gp expression.
Discussion
In clinical practice, a challenging problem in of drug therapy is individual variations in patient response. Environmental, genetic, and pathophysiologic factors are known contributors to variation in drug responses and adverse effects; however, little attention has been given to the impact of food and diet on drug disposition. Thus, the results in this report help further our knowledge of how diet impacts drug absorption. Specifically, the current work revealed that calorie restriction can increase the expression of intestinal Abcb1a, and decrease drug absorption. Because Abcb1a transports a wide variety of therapeutics, these results in mice beg the question of whether this phenomenon might also occur in humans.
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The gastrointestinal tract functions to digest and absorb nutrients from the diet.
However, this organ is also exposed to ingested xenobiotics, and thus also functions as a defense barrier, expressing many metabolic enzymes and efflux transporters. Modulation of efflux transporter expression or function in the intestinal tract can lead to altered systemic and local xenobiotic concentrations (Huang et al., 2010; Murakami and Takano, 2008) . The best characterized efflux transporter is P-gp. It is located apically on enterocytes and transports substrates back into the intestinal lumen, resulting in lowered systemic drug concentrations. digoxin is that it is not significantly metabolized in mice (Kawahara et al., 1999; Mayer et al., 1997; Schinkel et al., 1997; Schinkel et al., 1995) . Although it is possible that digoxin is transported by other transporters (Taub et al., 2011) , our observation that calorie restricted Abcb1a/b-null mice did not have decreased plasma concentration or increase the digoxin content of intestine compared to ad libitum Abcb1a/b-null mice. This suggests that the altered digoxin concentrations observed in calorie restricted wild-type mice is most likely due to altered P-gp expression. Additionally, digoxin is almost exclusively excreted by the gut mucosa (Mayer, et al., 1996) , thus it is not likely that the decrease in plasma digoxin concentrations is due to altered P-gp expression in kidney or liver.
In rats, protein-calorie malnutrition suppresses the hepatic expression of P-gp causing reduced canalicular excretion of the P-gp substrate daunomycin (Lee et al., 2003) . These results are opposite of what we observed in intestinal tissue (present study) and hepatic tissue (Renaud, et al., 2014) . However, the two studies are difficult to compare due to species and diet differences. The protein-calorie restricted diet in the study by Lee et al.
(2003) was iso-caloric to the control diet, but contained only 20% of the protein (qualitative malnutrition). However, in the present study and our previous study (Renaud, et al., 2014) , the calorie restricted mice received 25% less of the entire diet compared to the amount consumed by mice fed ad libitum (quantitative malnutrition). Nevertheless, it is evident that the quantity and the composition of the diet are certainly capable of modulating P-gp expression in both rats and mice.
A calorie restricted diet can arise out of choice (weight loss strategy), or from complications of an illness or drug therapy. Appetite loss leading to a calorie restricted diet often occurs in cancer and AIDS patients, which is particularly relevant to this study because P-gp transports many chemotherapeutics as well as HIV-antiviral therapies. Thus, the results
1 5 from this study showing that calorie restriction can alter the absorption of a P-gp substrate have implications for pharmacokinetic research and clinical practice.
In summary, this paper indicates that a calorie restricted diet can affect the absorption of P-gp substrates in mice is probably due to induced expression of intestinal P-pg. This study further underscores the importance of evaluating the influence of diet on drug disposition.
Determining how the diet can influence drug pharmacokinetics is prudent to improving our understanding of inter-individual differences in response to therapeutic agents. 
